| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $10.9M | — | +10.4% |
| SG&A Expense | $4.6M | — | +2.9% |
| Operating Income | -$15.5M | — | -8.0% |
| Net Income | -$14.8M | — | -7.8% |
| EPS (Basic) | -$0.13 | — | +51.9% |
| EPS (Diluted) | -$0.13 | — | +51.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $90.4M | +66.8% | +48.5% |
| Current Assets | $93.8M | +13.7% | +41.2% |
| Total Assets | $102.1M | +12.2% | +32.3% |
| Current Liabilities | $4.2M | -39.7% | -41.9% |
| Total Liabilities | $6.3M | -27.2% | -34.4% |
| Stockholders' Equity | $95.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.4M | — | -11.6% |
| Investing Cash Flow | $23.8M | — | +52.9% |
| Financing Cash Flow | $25.8M | — | — |
| +41.8% |